In the high-pressure world of pharmaceutical research and development, the line between visionary investment and speculative excess is thinner than ever. Last year, Bristol Myers Squibb (BMS) underscored the sheer scale of modern drug development capital when it committed a staggering $1.5 billion upfront—with potential total deal values reaching $11.1 billion—to partner with BioNTech on pumitamig, an investigational bispecific antibody targeting PD-L1 and VEGF-A.
This massive financial commitment serves as a lightning rod for a growing industry trend: the willingness of major drugmakers to wager billions on clinical platforms that have yet to fully mature. While the science behind these "blockbuster-in-waiting" candidates is compelling, the financial structures surrounding them raise a fundamental question: Is the industry buying into proven medicine, or is it paying "promise prices" based on nothing more than the premise of a successful outcome?
The Anatomy of a Multi-Billion Dollar Bet
The core of the BMS-BioNTech partnership is the pursuit of next-generation immunotherapy. By simultaneously blocking PD-L1—a protein that helps tumors evade immune detection—and VEGF-A, a signal that promotes blood vessel growth to feed tumors, developers hope to create a "double-hit" therapy that is more effective than current standards of care.
This approach, while conceptually sound, carries significant risk. The $11.1 billion potential valuation is heavily back-loaded, contingent on a gauntlet of development, regulatory, and commercial milestones. It is a quintessential example of the "tension" inherent in modern drug development: the necessity of deploying enormous capital before the data provides absolute certainty.
Industry experts, including Mike Rea, CEO of the R&D decision-making firm Then, If…, suggest that this creates a dangerous psychological environment. "Companies are paying promise prices on premise evidence," Rea notes. "A rational early bet should identify the exact premise that must hold for the price to make sense, specify when that will be tested, and define the ‘walk-away’ point. Hype is when the premise is inferred simply from the fact that other people have bought into it."
PD-(L)1/VEGF: The Race for Global Validation
The sector currently viewing the most rapid transition from "intriguing signal" to "strategic priority" is the PD-(L)1/VEGF bispecific field. The strategy has been bolstered by the performance of ivonescimab, developed by Akeso and licensed to Summit Therapeutics.
Chronology of Clinical Evidence
- The Breakthrough: In the China-based phase 3 HARMONi-2 trial, ivonescimab demonstrated a 49% reduction in the risk of progression or death compared to Merck’s industry-leading Keytruda in PD-L1-positive non-small cell lung cancer (NSCLC).
- The Complexity: A subsequent multiregional trial (HARMONi) in EGFR-mutated NSCLC met its progression-free survival (PFS) primary endpoint, but narrowly missed the statistical significance threshold for overall survival (OS) at the prespecified primary analysis.
- The Current State: While longer follow-up data has shown a positive OS trend, the initial statistical miss underscores the difficulty of translating regional clinical success into global regulatory approval.
Summit Therapeutics maintains that the evidence base is robust, pointing to over 5,000 patients treated across their and Akeso’s programs. However, the next phase of the battle will take place in global first-line phase 3 studies. These trials will be the true "litmus test" to determine if the efficacy observed in specific, localized populations can be replicated across diverse, global patient cohorts.
B7-H3 ADCs: Moving Toward Target Validation
If PD-(L)1/VEGF is still fighting for global consensus, B7-H3 antibody-drug conjugates (ADCs) appear closer to reaching an inflection point of "target validation." This year, two independently developed B7-H3-directed ADCs—GSK’s risvutatug rezetecan (Ris-Rez) and MediLink’s tambotatug pelitecan (Tam-Peli)—delivered significant phase 3 survival benefits in relapsed small cell lung cancer (SCLC) trials conducted in China.
Supporting Data Highlights
- GSK’s Ris-Rez: Reported a 54% reduction in the risk of death compared to chemotherapy, with median OS reaching 18.5 months versus 10.3 months.
- MediLink’s Tam-Peli: Also achieved a 54% reduction in death risk, with median OS of 13.3 months versus 9.4 months for the control arm.
The simultaneous success of two different drugs targeting the same protein is a powerful signal. Eric Richards, Senior VP and head of oncology product leadership at GSK, emphasizes that while these results strengthen the case for B7-H3 as a "clinically actionable target," the industry must avoid oversimplification.
"It is important to separate the biological rationale for the target from the clinical evidence for an individual ADC," Richards notes. "Performance is a composite of the target, the antibody, the linker, the payload, and the drug-antibody ratio." Even with two phase 3 wins, the field is cautious; the next hurdle is global reproducibility, as the industry moves to see if these Chinese trial results hold up under the scrutiny of Western regulatory bodies.
In Vivo CAR-T: The Chasm Between Strategy and Data
Perhaps the most dramatic example of "money leading the dataset" is the field of in vivo CAR-T therapy. Traditional CAR-T treatments are logistically complex, requiring the removal and external engineering of a patient’s immune cells. In vivo CAR-T attempts to bypass this by delivering genetic instructions to reprogram T cells directly inside the patient’s body.
The potential is transformative, promising lower costs and broader patient access. However, the current clinical data remains in its infancy. Lilly’s recent $7 billion acquisition of Kelonia Therapeutics was based on a phase 1 study of just six patients. While those six patients showed promising responses, they represent a microscopic sample size with limited follow-up time.
Johnson & Johnson’s recent collaboration with Sail Biomedicines for up to $2.58 billion further illustrates the sector’s aggressive stance. By investing heavily in a modality that has yet to prove its durability or safety compared to established ex-vivo CAR-T, these companies are betting on the future of the technology, not its current state. As it stands, the in vivo CAR-T space is defined by the sharpest gap between strategic conviction and definitive clinical proof.
Implications: When Deals Masquerade as Evidence
The overarching danger in this "deal-first" approach is the erosion of objective evaluation. As Mike Rea aptly puts it, "Price stands in for proof, and the more deals there are, the less anyone remembers that no new evidence has been added."
The Strategic Feedback Loop
- Internal Validation: A high-value deal creates an internal "development thesis." The company is then locked into a roadmap that assumes the technology works, which can lead to "sunk cost" biases if clinical data begins to falter.
- External Signaling: When a major pharma firm pays billions for an early-stage asset, it acts as a signal to the broader market. Investors and competitors interpret the deal as validation, potentially inflating the value of other, less-proven assets in the same space.
- The Confounding Variable: Because many of these new therapies share similar payloads or structural designs, a "win" for one drug is often mistakenly attributed to the entire class. This leads to an industry-wide rush into fields where the fundamental "confound" (e.g., whether the drug works because of the target or because of the payload) remains unresolved.
Conclusion: The Path Toward Maturity
The pharmaceutical industry is currently in an era of unprecedented capital deployment. While the drive for innovation and the search for the "next big thing" in oncology are vital, the industry must remain tethered to the scientific method.
The current landscape demonstrates that while conviction is a prerequisite for R&D, it is not a substitute for clinical validation. Whether it is the global testing of PD-L1/VEGF bispecifics, the class-wide verification of B7-H3 ADCs, or the long-term proof of in vivo CAR-T safety and durability, the next five years will be decisive. For these multi-billion dollar bets to pay off, pharma must ensure that they are not merely paying for the promise of success, but are actively building the data-driven foundations required to deliver it.
Ultimately, the market will correct for hype. The companies that emerge as leaders will not be those that simply outspent their rivals, but those that correctly identified the "premise" of their investments and had the scientific rigor to prove them in the clinic—rather than just at the negotiating table.
About the Author
